Cargando…
An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity
[Image: see text] We report the development of a high-throughput, intracellular “transcription block survival” (TBS) screening platform to derive functional transcription factor antagonists. TBS is demonstrated using the oncogenic transcriptional regulator cJun, with the development of antagonists t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088798/ https://www.ncbi.nlm.nih.gov/pubmed/35557753 http://dx.doi.org/10.1021/jacsau.2c00105 |
_version_ | 1784704386163802112 |
---|---|
author | Brennan, Andrew Leech, James T. Kad, Neil M. Mason, Jody M. |
author_facet | Brennan, Andrew Leech, James T. Kad, Neil M. Mason, Jody M. |
author_sort | Brennan, Andrew |
collection | PubMed |
description | [Image: see text] We report the development of a high-throughput, intracellular “transcription block survival” (TBS) screening platform to derive functional transcription factor antagonists. TBS is demonstrated using the oncogenic transcriptional regulator cJun, with the development of antagonists that bind cJun and prevent both dimerization and, more importantly, DNA binding remaining a primary challenge. In TBS, cognate TRE sites are introduced into the coding region of the essential gene, dihydrofolate reductase (DHFR). Introduction of cJun leads to TRE binding, preventing DHFR expression by directly blocking RNA polymerase gene transcription to abrogate cell proliferation. Peptide library screening identified a sequence that both binds cJun and antagonizes function by preventing DNA binding, as demonstrated by restored cell viability and subsequent in vitro hit validation. TBS is an entirely tag-free genotype-to-phenotype approach, selecting desirable attributes such as high solubility, target specificity, and low toxicity within a complex cellular environment. TBS facilitates rapid library screening to accelerate the identification of therapeutically valuable sequences. |
format | Online Article Text |
id | pubmed-9088798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-90887982022-05-11 An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity Brennan, Andrew Leech, James T. Kad, Neil M. Mason, Jody M. JACS Au [Image: see text] We report the development of a high-throughput, intracellular “transcription block survival” (TBS) screening platform to derive functional transcription factor antagonists. TBS is demonstrated using the oncogenic transcriptional regulator cJun, with the development of antagonists that bind cJun and prevent both dimerization and, more importantly, DNA binding remaining a primary challenge. In TBS, cognate TRE sites are introduced into the coding region of the essential gene, dihydrofolate reductase (DHFR). Introduction of cJun leads to TRE binding, preventing DHFR expression by directly blocking RNA polymerase gene transcription to abrogate cell proliferation. Peptide library screening identified a sequence that both binds cJun and antagonizes function by preventing DNA binding, as demonstrated by restored cell viability and subsequent in vitro hit validation. TBS is an entirely tag-free genotype-to-phenotype approach, selecting desirable attributes such as high solubility, target specificity, and low toxicity within a complex cellular environment. TBS facilitates rapid library screening to accelerate the identification of therapeutically valuable sequences. American Chemical Society 2022-04-06 /pmc/articles/PMC9088798/ /pubmed/35557753 http://dx.doi.org/10.1021/jacsau.2c00105 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brennan, Andrew Leech, James T. Kad, Neil M. Mason, Jody M. An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity |
title | An Approach to Derive Functional Peptide Inhibitors
of Transcription Factor Activity |
title_full | An Approach to Derive Functional Peptide Inhibitors
of Transcription Factor Activity |
title_fullStr | An Approach to Derive Functional Peptide Inhibitors
of Transcription Factor Activity |
title_full_unstemmed | An Approach to Derive Functional Peptide Inhibitors
of Transcription Factor Activity |
title_short | An Approach to Derive Functional Peptide Inhibitors
of Transcription Factor Activity |
title_sort | approach to derive functional peptide inhibitors
of transcription factor activity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088798/ https://www.ncbi.nlm.nih.gov/pubmed/35557753 http://dx.doi.org/10.1021/jacsau.2c00105 |
work_keys_str_mv | AT brennanandrew anapproachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity AT leechjamest anapproachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity AT kadneilm anapproachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity AT masonjodym anapproachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity AT brennanandrew approachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity AT leechjamest approachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity AT kadneilm approachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity AT masonjodym approachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity |